义翘神州 reported revenue of ¥0.39B for the period ended 2026-06-30, +21.1% year on year. Net income was ¥0.09B, a 21.7% net margin on a 74.9% gross margin. The largest revenue line is 重组蛋白 at 45% of the total. Free cash flow for the period was ¥0.00B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥0.39B | +21.1% |
| Gross profit | ¥0.29B | — |
| Operating income | ¥0.10B | — |
| Net income | ¥0.09B | +25.9% |
| Gross margin | 74.9% | Net margin 21.7% |
| Revenue Q/Q | +14.2% | — |
| Segment | Revenue | Share |
|---|---|---|
| 重组蛋白 | ¥0.18B | 44.7% |
| CRO服务 | ¥0.13B | 31.9% |
| 抗体 | ¥0.06B | 15.2% |
| 房屋租赁及配套 | ¥0.01B | 3.5% |
| 培养基 | ¥0.01B | 3.2% |
| 基因 | ¥0.00B | 0.9% |
| 其他 | ¥0.00B | 0.5% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥0.10B | 25.1% |
| R&D | ¥0.04B | 10.9% |
| SG&A | ¥0.17B | 43.2% |
| Tax & other | ¥0.02B | 4.5% |
| Item | Amount |
|---|---|
| Total assets | ¥5.45B |
| Total liabilities | ¥0.22B |
| Shareholders' equity | ¥5.23B |
| Equity / assets | 96.0% |
| Operating cash flow | ¥0.05B |
| Capital expenditure | ¥0.04B |
| Free cash flow | ¥0.00B |
| Cash conversion (OCF / net income) | 108% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
金鹰重工 ・ 超越科技 ・ 雷电微力 ・ 信濠光电 ・ 果麦文化 ・ 远信工业 ・ 张小泉 ・ 森赫股份 ・ 汇隆新材 ・ 中粮科工 ・ 金三江 ・ 兰卫医学
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies